PIPELINE A pipeline built to address significant unmet need
We aim to improve the lives of people with schizophrenia by specifically targeting negative symptoms. This focus reflects an entirely new, broader shift in how the disorder can be treated.
- 5-HT2A antagonist
- Sigma2 antagonist
- α1A-adrenegic antagonist
Roluperidone’s potential for Schizophrenia
Roluperidone is an investigational therapy designed to treat negative symptoms of schizophrenia by targeting serotonin, sigma, and α-adrenergic receptors—pathways involved in mood, cognition, sleep, and motivation. Rather than targeting a specific biomarker, we designed roluperidone to address a broad range of patient-observed negative symptoms.
Supported by Phase 2b and Phase 3 clinical data, roluperidone is the only investigational medicine to demonstrate statistically significant improvement in the primary negative symptoms of schizophrenia. In clinical studies, treatment was associated with improvements in functioning and avolition, without worsening positive symptoms or increasing anxiety and depression. As a monotherapy, roluperidone has also shown a low rate of relapse of positive symptoms.
For more information on our confirmatory Phase 3 clinical trial investigating roluperidone in schizophrenia, visit our Clinical Trials page.
